A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Inclusion criteria:

Stable/chronic plaque psoriasis with PASI score of ≥ 12 AND involving ≥ 10% of the subject's BSA.- ≥ 30 years of age at time of consent.
BMI ≥ 30 kg/m2
LDL ≥ 100 mg/dL at Screening.
All females must have a negative serum pregnancy test result at Screening and a negative urine pregnancy test prior to dosing.

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria are met:

Past use of orticumab.
Any of the nonplaque forms of psoriasis: erythrodermic, guttate, or pustular.
Scalp, palmar or plantar psoriasis only, at Screening or Baseline.
Have evidence of skin conditions (e.g., eczema) at the time of Screening or Baseline visit that would interfere with theevaluation of psoriasis.
Newly discovered Type 2 diabetes mellitus (T2DM)
Moderate or high-intensity statin use or new use of a low-intensity statin therapy.
No use of anti-coagulating or anti-thrombotic agents.
Poorly controlled hypertension
Use of an IL-23 blocker in the past 180 days, an IL-17 blocker in the past 16 weeks, or a TNF blocker in the past 12 weeks.
Use of methotrexate, cyclosporine, or apremilast in the past 4 weeks.
History of hypersensitivity or allergies to any contents in the orticumab formulation.
A history of any clinically important abnormalities in cardiac rhythm or conduction.
A history of prolonged QT intervals or a family history of long QT-syndrome at Screening.
A history of first, second or third-degree atrioventricular (AV) block, or AV dissociation.
A history of complete bundle branch block.
Unstable angina pectoris, myocardial infarction, transient ischemic attack, or stroke within 3 months prior to Screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within 6 months prior to Screening or who are due to undergo these procedures at the time of Screening.
Severe congestive heart failure (NYHA III or IV).